Welcome to BioSeeker Group!

Currently Druggable in Prostate Cancer: A Drug Target Competitive Analysis

Additional Information

Published Date Sep 8, 2008
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 306
PDF Fact Sheet View Fact Sheet for the report Currently Druggable in Prostate Cancer: A Drug Target Competitive Analysis in PDF
Format PDF
Publisher BioSeeker Group
Product Line View All Available Cancer Highlights Reports

Availability: In stock

$1,950.00

Quick Overview

This report is an open landscape of resources to build, fuel, and drive your scientific competitive vehicle for the advancement of prostate cancer drugs.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Currently Druggable in Prostate Cancer: A Drug Target Competitive Analysis.

    To find out more about Currently Druggable in Prostate Cancer: A Drug Target Competitive Analysis, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Currently Druggable in Prostate Cancer: A Drug Target Competitive Analysis is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This report aims to analyze the current and future potential of prostate cancer pipeline by examining key fundamentals across the entire pipeline of drug candidates. BioSeeker has identified three fundamental dimensions to outline the competitive landscape within the pharmaceutical industry; compound type, therapy area and target type.

This report is written for you to identify your competition and understand which targeting strategies are at work within prostate cancer drug development. It allows you to pin-point which competitors drugs’ clinical out-come may have bearing on your own drug development and who are developing sequels to blockbuster drugs. This report also helps you to locate white-spots in the competitive landscape, giving you little or no competition. Conversely it may reveal unexpected competition for you.

Drug targets are the critical link between drugs and their role in the treatment of medical disorders. BioSeeker has surveyed the prostate cancer field and identified 135 drug targets belonging to 193 drugs. This report, Currently Druggable in Prostate Cancer: A Drug Target Competitive Analysis is an open landscape of resources to build, fuel, and drive your scientific competitive vehicle for the advancement of prostate cancer drugs.

In the report, BioSeeker reports on 116 unique drug target combinations, each comprised of a different collection or mix of individually defined targets, for 193 prostate cancer drugs. The highest degree of distinctiveness among the cancer drugs is achieved by sorting each of them according to drug target mix, compound type and R&D approach. At the same time we are also identifying peer groups of drugs, that is, drugs we consider suitable for head-to-head comparison during drug development.

To fuel the scientific and competitive thinking, BioSeeker opens the gate into the presence and relevance of protein-protein interactions between identified targets of prostate drugs. No less than 300+ target-target interactions were recognized among and between 110 of the 135 included prostate cancer drug targets.

Why You Should Own Your Own Copy of this Report:

  • 300+ pages, with more than 50 different tables and figures. Includes more than 1,000 active links to drug target related resources on the Internet
  • A 193 prostate cancer drugs analysis, under development by 135 investigators
  • 135 unique, in-depth, drug target validating profiles, highlighting twelve themes about the drug target, i.e. protein-protein interaction with other prostate cancer drug targets, pursued cancer indications, drugs under development, presence in the Cancer Genome Project etc.
  • A unique drug target combination breakdown of prostate cancer drugs into R&D approaches
  • Unique drug-protein target interactome- and protein-protein interactome of drug targets analysis
  • Pathway profiling of prostate cancer drug targets
  • Compound strategies based on sub-cellular localization of drug targets
  • Expression levels of identified drug targets in prostate cancer tissue
  • Structure based drug design in prostate cancer
  • Pin-point which competitor drugs’ clinical out-come may have bearing on your own drug development
  • Who are working on sequels to blockbuster drugs?
  • Locate white-spots in the competitive landscape, giving you little or no competition

In all, this report is a serious reference for any professional interested in the development of oncology drug targets and the selection/validation of targeting strategies.

1 Executive Summary

2 About Cancer Highlights

3 Methodologies

4 4.1 List of Figures
4.2 List of Tables

5 How to Use this Report

6 Compound Strategies based on Sub-Cellular Localization of Prostate Cancer Drug
Targets

7 The Cancer Genome Project and Prostate Cancer Targets
7.1 Prostate Cancer Targets Present in the Cancer Gene Census and in the Catalogue of
Somatic Mutations in Cancer

8 Expression Levels of Identified Drug Targets in Prostate Cancer Tissue

9 Pathway Analysis of Prostate Cancer Drugs

10 Target-Target Interactions among Identified Prostate Cancer Targets

11 Structure-based Drug Design in Prostate Cancer is Stimulated by Available Structure
Data on Biological Targets

12 Drug Target Profiles of Prostate Cancer Drugs
12.1.1 Acid Phosphatase Activity Targets
12.1.2 Carboxy-Lyase Activity Targets
12.1.3 Carboxypeptidase Activity Targets
12.1.4 Catalytic Activity Targets
12.1.5 Cell Adhesion Molecule Activity Targets
12.1.6 Chaperone Activity Targets
12.1.7 Chemokine Activity Targets
12.1.8 Complement Activity Targets
12.1.9 Cysteine-Type Peptidase Activity Targets
12.1.10 Cytokine Activity Targets
12.1.11 DNA Repair Protein Targets
12.1.12 DNA Topoisomerase Activity Targets
12.1.13 DNA-Directed DNA Polymerase Activity Targets
12.1.14 G-Protein Coupled Receptor Activity Targets
12.1.15 Growth Factor Activity Targets
12.1.16 Hydrolase Activity Targets
12.1.17 Kinase Activity Targets
12.1.18 Ligand-Dependent Nuclear Receptor Activity Targets
12.1.19 Ligase Activity Targets
12.1.20 Lipid Kinase Activity Targets
12.1.21 Lipid Phosphatase Activity Targets
12.1.22 Metallopeptidase Activity Targets
12.1.23 Molecular Function Unknown Targets
12.1.24 Motor Activity Targets
12.1.25 Oxidoreductase Activity Targets
12.1.26 Peptide Hormone Targets
12.1.27 Protein Binding Targets
12.1.28 Protein Serine/Threonine Kinase Activity Targets
12.1.29 Protein-Tyrosine Kinase Activity Targets
12.1.30 Receptor Activity Targets
12.1.31 Receptor Binding Targets
12.1.32 Receptor Signaling Complex Scaffold Activity Targets
12.1.33 Receptor Signaling Protein Serine/Threonine Kinase Activity Targets
12.1.34 RNA Binding Targets
12.1.35 RNA-Directed DNA Polymerase Activity Targets
12.1.36 Serine-Type Peptidase Activity Targets
12.1.37 Structural Constituent of Cytoskeleton Targets
12.1.38 Structural Molecule Activity Targets
12.1.39 Superoxide Dismutase Activity Targets
12.1.40 T Cell Receptor Activity Targets
12.1.41 Transcription Factor Activity Targets
12.1.42 Transcription Regulator Activity Targets
12.1.43 Translation Regulator Activity Targets
12.1.44 Transmembrane Receptor Activity Targets
12.1.45 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets
12.1.46 Transporter Activity Targets

13 The Drug-Target Interactome

14 The Progression and Maturity of Prostate Cancer Targets
14.1 Target Profiles of Prostate Cancer Drugs in Pre-Registration or on the Market
14.2 New and Unique Prostate Cancer Targets in Phase III Clinical Development
14.3 New and Unique Prostate Cancer Targets in Phase II Clinical Development
14.4 New and Unique Prostate Cancer Targets in Phase I Clinical Development
14.5 New and Unique Prostate Cancer Targets in Preclinical Development
14.6 Development Profiles of All Prostate Cancer Target Combinations

15 Targets by R&D Approach in Prostate Cancer
15.1 Small Molecules
15.1.1 Background
15.1.2 Targets in Prostate Cancer
15.2 Peptide/Protein Drugs
15.2.1 Background
15.2.2 Targets in Prostate Cancer
15.3 Monoclonal Antibodies and Antibody-Like Structures
15.3.1 Background
15.3.2 Targets in Prostate Cancer
15.4 Nucleic Acid Therapies
15.4.1 Background
15.4.2 Targets in Prostate Cancer
15.5 Cell and Gene Therapy
15.5.1 Background
15.5.2 Targets in Prostate Cancer
15.6 Drug Delivery and Nanotechnology
15.6.1 Background
15.6.2 Targets in Prostate Cancer

16 Prostate Cancer Targets by Companies
16.1 Australia
16.2 Canada
16.3 Denmark
16.4 Finland
16.5 France
16.6 Germany
16.7 India
16.8 Ireland
16.9 Israel
16.10 Italy
16.11 Japan
16.12 Netherlands
16.13 Norway
16.14 Spain
16.15 Sweden
16.16 Switzerland
16.17 United Kingdom
16.18 USA
16.19 Non-Industrial Bodies

17 Drug Index

18 Company Index

4.1 List of Figures
Figure 1: Distribution of Compound Types among Prostate Cancer Drugs
Figure 2: Primary Sub-cellular Localization of Drug Targets
Figure 3: Visualization of Protein-Protein Interactions Among Antibody Drug Targets
Figure 4: The Drug-Protein Interactome of Prostate Cancer Drugs – Main Clusters
Figure 5: The Drug-Protein Interactome of Prostate Cancer Drugs – Smaller Clusters
Figure 6: Head-to-Head Targeting Interactome of Prostate Cancer Drugs

4.2 List of Tables
Table 1: Compound Strategies based on Sub-Cellular Localization of Prostate Cancer Drug Targets
Table 2: Drug Targets of Prostate Cancer Drugs Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census
Table 3: Expression Levels of Identified Drug Targets in Prostate Cancer Tissue
Table 4: Pathway Summary
Table 5: Drug Targets without any Identified Assigned Pathways
Table 6: Pathway Profile According to BioCarta of Prostate Cancer Drug Targets
Table 7: Pathway Profile According to BioCarta of Prostate Cancer Drug Targets
Table 8: Pathway Profile According to BioCarta of Prostate Cancer Drug Targets
Table 9: Target-Target Interactions among Prostate Cancer Drug Targets
Table 10: Identity of Prostate Cancer Drug Targets with Available Biological Structures
Table 11: Overview of Drug Target Profile Themes
Table 12: Drug-Protein Interactome Clusters
Table 13: Fall Out in Terms of the Total Number of Drug Target Mixes, Drugs, and the Presence of New Drug Target Mixes by Developmental Stage
Table 14: Top 5 Competitive Prostate Cancer Targets
Table 15: Target Profiles of Prostate Cancer Drugs in Pre-Registration or on the Market
Table 16: New and Unique Prostate Cancer Targets in Phase III Clinical Development
Table 17: New and Unique Prostate Cancer Targets in Phase II Clinical Development
Table 18 New and Unique Prostate Cancer Targets in Phase I Clinical Development
Table 19: New and Unique Prostate Cancer Targets in Preclinical Development
Table 20: The Progression, Maturity and Competitive Comparison of Prostate Cancer Drug Targets in Development
Table 21: Number of Prostate Cancer Drug Target Mixes Reported by Line of Therapy
Table 22: Number of Head-to-head Competing Small Molecule Drugs for the Treatment of Prostate Cancer by Drug Target
Table 23: Drug Targets of Small Molecule Drugs in Prostate Cancer
Table 24: Mechanistic Relationship between Small Molecule Drugs in Prostate Cancer
Table 25: Drug Targets of Peptide Based Drugs in Prostate Cancer
Table 26: Drug Targets of Protein Based Drugs in Prostate Cancer
Table 27: Drug Targets of Monoclonal Antibodies and Antibody-Like Drugs in Prostate Cancer
Table 28: Drug Targets of Nucleic Acid Therapies in Prostate Cancer
Table 29: Potential Forms of Cell Therapy
Table 30: Vectors in Gene Therapy
Table 31: Drug Targets of Cell Therapies in Prostate Cancer
Table 32: Drug Targets of Gene Therapies in Prostate Cancer
Table 33: Drug Targets with New Drug Delivery Strategies in Prostate Cancer
Table 34: Prostate Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Australia
Table 35: Prostate Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Canada
Table 36: Prostate Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Denmark
Table 37: Prostate Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Finland
Table 38: Prostate Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in France .
Table 39: Prostate Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Germany
Table 40: Prostate Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in India
Table 41: Prostate Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Ireland
Table 42: Prostate Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Israel
Table 43: Prostate Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Italy
Table 44: Prostate Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Japan
Table 45: Prostate Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Netherlands
Table 46: Prostate Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Norway
Table 47: Prostate Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Spain
Table 48: Prostate Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Sweden
Table 49: Prostate Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Switzerland
Table 50: Prostate Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in United Kingdom
Table 51: Prostate Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in USA
Table 52: Prostate Cancer Drugs with Drug Target Mix and Developmental Projects by Non-Industrial Bodies

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Currently Druggable in Prostate Cancer: A Drug Target Competitive Analysis.
    To find out more about Currently Druggable in Prostate Cancer: A Drug Target Competitive Analysis, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Currently Druggable in Prostate Cancer: A Drug Target Competitive Analysis is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Cancer Highlights' category:


Lymphoma Drug Development Strategies at Work - Define Your Competition
This report will be an important part of creating and implementing a market development plan for any lymphoma therapeutic drug to ensure that the optimal market conditions exist by the time the product is commercialized. Learn More


The Deployment of Antibody Technologies for the Advancement of Cancer Therapeutics
The discovery of new cancer therapeutics has seen a significant shift towards biologicals as an alternative to small molecule drugs. Targeted biologics utilizing monoclonal antibody-based technologies have rapidly developed into one of the major market segments of the pharmaceutical industry. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Protein Kinase Inhibitors, Antibodies and Peptides
This triple analysis focuses on cancer drug development strategies by the mechanism/target/effect of Protein Kinase Inhibitors and by the two compound strategies of Antibodies and Peptides. Learn More


Triple Analysis: Lymphoma, Pancreatic Cancer and Protein Kinase Inhibitors
This triple analysis focuses on cancer drug development strategies in both Lymphoma and Pancreatic Cancer and by the mechanism/target/effect of Protein Kinase Inhibitors. Learn More